Marinus Pharmaceuticals
22
0
0
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
22.7%
5 terminated/withdrawn out of 22 trials
76.2%
-10.3% vs industry average
32%
7 trials in Phase 3/4
119%
19 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (22)
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
Role: lead
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
Role: lead
Randomized Therapy In Status Epilepticus
Role: lead
Open-label Extension to Protocol 1042-0500
Role: lead
To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)
Role: lead
Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)
Role: lead
Ganaxolone Expanded Access Program Compassionate Use
Role: lead
A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression
Role: lead
A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression
Role: lead
A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures
Role: lead
Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)
Role: lead
A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms
Role: lead
Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder
Role: lead
Ganaxolone Treatment in Children With Fragile X Syndrome
Role: lead
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)
Role: lead
Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies
Role: lead
A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures
Role: lead
Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus
Role: lead
Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension
Role: lead
Open-label Extension to Protocol 1042-0600
Role: lead